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Abstract 
The increasing incidence of fungal infections and damages due to drug-resistant fungi urges the development of 
new antifungal strategies. The cysteine-rich antifungal proteins from filamentous ascomycetes provide a feasible base 
for protection against molds due to their potent antifungal activity on them. In contrast to this, they show no or weak 
activity on yeasts, hence their applicability against this group of fungi is questionable. In the present study a 5.6 kDa 
anti-yeast protein (NFAP2) is isolated, identified and characterized from the ferment broth of Neosartorya fischeri NRRL 
181. Based on a phylogenetic analysis, NFAP2 and its putative homologs represent a new group of ascomycetous 
cysteine-rich antifungal proteins. NFAP2 proved to be highly effective against tested yeasts involving clinically relevant 
Candida species. NFAP2 did not cause metabolic inactivity and apoptosis induction, but its plasma membrane disrup-
tion ability was observed on Saccharomyces cerevisiae. The antifungal activity was maintained after high temperature 
treatment presumably due to the in silico predicted stable tertiary structure. The disulfide bond-stabilized, heat-
resistant folded structure of NFAP2 was experimentally proved. After further investigations of antifungal mechanism, 
structure and toxicity, NFAP2 could be applicable as a potent antifungal agent against yeasts.
Keywords: Neosartorya fischeri, Protein isolation, Cysteine-rich antifungal protein, Anti-yeast activity, Candida spp., 
Protein structure
© 2016 The Author(s). This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made.
Introduction
From the second half of the 1990s several extracellular 
cysteine-rich antifungal proteins have been isolated and 
characterized from filamentous ascomycetes. The main 
features of this protein group are a cationic character due 
to a high amount of arginine and lysine residues, a low 
molecular mass and the presence of six to eight cysteine 
residues that form three to four intra-molecular disulfide 
bonds which provide a high stability against protease 
degradation, high temperature and broad pH range. They 
show potent antifungal activity against several opportun-
istic human, animal, plant and food-borne pathogenic 
filamentous fungi (Marx 2004; Meyer 2008; Galgóczy 
et  al. 2010; Delgado et  al. 2015). Based on in  vitro and 
in vivo interaction and toxicological studies (Marx 2004; 
Marx et al. 2008; Meyer 2008; Galgóczy et al. 2010; Palicz 
et al. 2013) the members of this protein group represent 
exceptionally suitable compounds of commercial drugs, 
biopesticides and preservatives against molds and offer 
an alternative, safely applicable solution for recent anti-
fungal challenges in the medicine (Miceli and Lee 2011), 
agriculture (Magan et al. 2011), biodiversity (Fisher et al. 
2012) and cultural heritage protection (Sterflinger and 
Pinzari 2012).
Beside the strong inhibitory effect on molds, weak 
anti-yeast activity is described at relative high concen-
trations of few cysteine-rich antifungal proteins from 
filamentous ascomycetes, i.e. Aspergillus niger antifungal 
protein (ANAFP; Lee et  al. 1999), Fusarium polyphial-
idicum antifungal protein (FPAP; Galgóczy et al. 2013a) 
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belonging to Penicillium chrysogenum antifungal protein 
(PAF)-cluster proteins, and Penicillium brevicompactum 
bubble protein (BP) from the BP-cluster proteins (Seibold 
et al. 2011).
In our previous work we demonstrated that the fila-
mentous ascomycete Neosartorya fischeri (anamorph: 
Aspergillus fischerianus) NRRL 181 isolate secretes a 
representative of the PAF-cluster proteins. We termed 
it Neosartorya fischeri antifungal protein (NFAP) 
(Kovács et  al. 2011), which effectively inhibits the 
growth of numerous filamentous ascomycetes (Virágh 
et  al. 2014), but it proved to be ineffective against 
yeasts.
In the present study a novel cysteine-rich antifun-
gal protein (Neosartorya fischeri antifungal protein 2, 
NFAP2) with high anti-yeast activity was isolated and 
identified from the supernatant of N. fischeri NRRL 181 
cultivated in a minimal medium. NFAP2 was character-
ized concerning its phylogenetic relationship with the 
other ascomycetous cysteine-rich antifungal proteins, 
antifungal effect, thermal stability, and structure.
Materials and methods
Strains and media
A minimal medium (MM: 2  % sucrose, 0.3  % NaNO3, 
0.05 % KCl, 0.05 % MgSO4 × 7 H2O, 0.005 % FeSO4 × 7 
H2O (w/v), 0.25  % 1  M potassium phosphate buffer pH 
5.8, 0.01  % trace element solution (v/v); trace element 
solution: 0.1 % FeSO4 × 7 H2O, 0.9 % ZnSO4 × 7 H2O, 
0.4  % CuSO4  ×  5 H2O, 0.01  % MnSO4  ×  H2O, 0.01  % 
H3BO3, 0.01  % Na2MoO4  ×  2 H2O (w/v)) was used to 
produce NFAP2 by N. fischeri NRRL 181 strain (Agri-
cultural Research Service Culture Collection, National 
Center for Agricultural Utilization Research, Peoria, Illi-
nois USA).
The antifungal activity of NFAP2, NFAP, and conven-
tional antifungal agents was investigated against nine 
yeasts (Candida albicans American Type Culture Col-
lection, Manassas, VA, USA, ATCC 10231; Candida 
glabrata Centraalbureau voor Schimmelcultures, Utre-
cht, The Netherlands, CBS 138; Candida guilliermondii 
CBS 566; Candida krusei CBS 573; Candida lusitaniae 
CBS 6936; Candida parapsilosis CBS 604; Candida tropi-
calis CBS 94; Saccharomyces cerevisiae Szeged Micro-
biological Collection, Szeged, Hungary, SZMC 0644; 
and Schizosaccharomyces pombe SZMC 0142), and three 
NFAP-sensitive filamentous fungal isolates (Aspergil-
lus nidulans Fungal Genetics Stock Center, Kansas, MO, 
USA, FGSC A4; Aspergillus niger SZMC 601; Rhizomu-
cor miehei CBS 360.92) (Kovács et al. 2011; Virágh et al. 
2015). Susceptibility tests were performed in low cati-
onic broth medium (LCM: 0.5  % glucose, 0.025  % yeast 
extract, 0.0125 % peptone (w/v)).
Filamentous fungi were maintained on malt extract 
agar slants (MEA: 0.5 % malt extract, 0.25 % yeast extract, 
1 % glucose, 2 % agar (w/v)), yeasts were maintained on 
yeast extract glucose medium (YEGK: 1  % glucose; 1  % 
KH2PO4; 0.5 % yeast extract, 2 % agar (w/v)) at 4 °C.
Isolation and purification of NFAP2
NFAP2 was isolated from the supernatant of N. fis-
cheri NRRL 181 culture, which was grown in MM. Five 
1  l-Erlenmeyer flasks each containing 200  ml MM was 
inoculated with 2 × 107 conidia and incubated for 7 days 
at 25  °C under continuous shaking at 210  rpm. Mycelia 
were removed with filtering the culture through paper 
filter (Rotilabo-round filters, type 111A; Carl Roth KG, 
Karlsruhe, Germany), then the mycelia-free supernatant 
was centrifuged (10,000×g, 17  °C) and filtered through 
paper filter (Fisherbrand QL115 folded filter paper, Fisher 
Scientific, Pittsburgh, PA, USA) again. NFAP2 was puri-
fied from this mycelia-free supernatant based on the 
slightly modified method described at NFAP previously 
(Virágh et  al. 2014). The <30  kDa molecular fraction of 
the supernatant was separated by ultrafiltration (Ultra-
cell 30  kDa Ultrafiltartion Discs, regenerated cellulose; 
Millipore, Billerica, MA, USA) then its protein content 
was purified by cation-exchange chromatography on a 
Bio-Scale™ Mini Macro-Prep® High S column (Bio-Rad 
Laboratories, Hercules, CA, USA) using the BioLogic 
Duo Flow™ system (Bio-Rad Laboratories, Hercules, CA, 
USA). The column was equilibrated with 10 mM sodium 
phosphate buffer (pH 6.6) containing 25  mM NaCl and 
0.15 mM EDTA. Bound proteins were eluted with NaCl 
gradient (0.0–1.5  M) prepared in 10  mM sodium phos-
phate buffer (pH 6.6) at a flow rate of 1.2 ml min−1. The 
quality of the NFAP2 fractions was checked by SDS-
PAGE (Novex™ 18  % Tris–Glycine Mini Protein Gels, 
1.0 mm, 10-well; Thermo Fisher Scientific, Waltham, MA, 
USA). Protein bands were visualized applying Coomassie 
Brilliant Blue R-250 and silver staining. The pool of the 
pure NFAP2 fractions was dialyzed (Snake Skin™ dialy-
sis tubing, 3.5 K MWCO, Thermo Scientific, Logan, UT, 
USA) against double distilled water, then lyophilized and 
dissolved in double distilled water. This protein solution 
was sterilized by syringe filtration (Millex-GV, PVDF, 
pore size: 0.22 µm; Millipore, Billerica, MA, USA).
Identification of NFAP2
Molar mass measurement of NFAP2 was performed 
on a Micromass Q-TOF Premier mass spectrometer 
(Waters MS Technologies, Manchester, UK) equipped 
with a nanoelectrospray ion source. Partial sequence of 
NFAP2 was determined from enzymatic digested pro-
tein sample. Ten microliter of protein solution contain-
ing 1 μg μl−1 protein was mixed with a buffer containing 
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25  mM NH4HCO3, pH 8.0, reduced with 10  mM DTT 
and alkylated with 55  mM iodoacetamide. The reduced 
and alkylated protein was purified with C4 containing 
ZipTip pipette tip (Millipore, Billerica, MA, USA) and it 
was subjected to enzymatic cleavage with 0.1 μg trypsin 
(Promega, Madison, WI, USA) solution (in 25  mM 
NH4HCO3) overnight at 37  °C. Then a mass spectro-
metric (MS) method was used, which was based on the 
database searching (Mascot Search Engine, NCBInr 
Database) of the protein fragment from the enzymatic 
digestion. The digested sample was analyzed on a Waters 
NanoAcquity UPLC (Waters MS Technologies, Man-
chester, UK) system coupled with a Micromass Q-TOF 
premier mass spectrometer. LC conditions were the fol-
lowings: flow rate: 350  nl  min−1; eluent A: water with 
0.1 % (v/v) formic acid, eluent B: acetonitrile with 0.1 % 
(v/v) formic acid; gradient: 40 min, 3–40 % (v/v) B eluent; 
column: Waters BEH130 C18 75  lm 250  mm−1 column 
with 1.7 μm particle size C18 packing (Waters, Milford, 
MA, USA). The mass spectrometer was operated in MSE 
and DDA mode with lockmass correction (standard: Glu-
1-Fibrinopeptide M +  2H +  m/z =  785.842). Acquired 
data derived from the enzymatic cleavage were processed 
by the ProteinLynx Global Server (Waters, Milford, MA, 
USA).
In silico investigations
The SignalP1 4.1 server was used to predict the cleav-
age site of the signal sequence (Petersen et  al. 2011). 
The molecular weight, pI, grand average of hydropathy 
(GRAVY) value, total net charge, and disulfide bridge 
pattern of the mature NFAP2 were predicted by ExPAsy 
ProtParam tool (Gasteiger et al. 2005), Protein Calculator 
v3.4 server (The Scripps Research Institute; http://www.
scripps.edu/~cdputnam/protcalc.html), and DISULFIND 
Cysteines Disulfide Bonding State and Connectivity Pre-
dictor server (Ceroni et al. 2006), respectively.
Phylogenetic analysis
The BioEdit program (Hall 1999) was used to examine 
the antifungal protein sequences. Similarity searches to 
NFAP2 in the NCBI, EXPASY and JGI databases were 
performed using the Basic Local Alingment Search Tool 
(BLAST; Pevsner 2009). All previously described, iso-
lated and characterized cysteine-rich antifungal proteins 
from filamentous ascomycetes, and the identified puta-
tive NFAP2 homologs were involved in the phylogenetic 
studies. Sequences were aligned by using the PRANK 
(Löytynoja and Goldman 2008). Ambiguously aligned 
positions were removed by GBlocks (Talavera and Cas-
tresana 2007). A maximum likelihood analysis (ML) was 
carried out under the WAG model of protein evolution 
with gamma distributed rate-heterogeneity and 1000 
bootstrap replicates. Bootstrap percentages were sum-
marized on the ML tree using the SumTrees script of 
the Dendropy package (Sukumaran and Holder 2010). 
Bootstrap proportions >70 % were considered as strong 
support.
Antifungal susceptibility tests
The in vitro antifungal effect of NFAP2, NFAP, and con-
ventional antifungal agents (Sigma-Aldrich, St Louis, 
MO, USA) representing polyenes (amphotericin B, 
AMB), azoles (fluconazole, FLC and itraconazole, ITC), 
allylamines (terbinafine, TRB), and echinocandins 
(caspofungin, CSP) against mid-log phase yeast cells 
(grown up in LCM at 30  °C under continuous shaking 
at 210  rpm) and conidia or sporangiospores of 4-days-
old filamentous fungi was examined in 96-well micro-
titer plate bioassays by measuring the optical density 
of the cultures. All conventional antifungal agents 
were dissolved in 96  % ethanol to prepare stock solu-
tions (10.24 mg ml−1). One hundred microliter of puri-
fied NFAP2 (0.195–50  µg  ml−1 in twofold dilution), or 
NFAP (25–400 µg ml−1 in twofold dilution), or antifun-
gal drug (128–0.25 µg ml−1 in twofold dilution) diluted 
in LCM was mixed with 100  µl of 105 cells or conidia 
or sporangiospores ml−1 suspension prepared also in 
LCM. The flat-bottom plates were incubated for 0, 24, 
48 and 72 h at 30 °C (yeasts), 25 °C (Aspergillus spp.), or 
37 °C (R. miehei) without shaking, and then the absorb-
ance (OD620) were measured in well scanning mode 
after shaking the plates for 5  s with a microtiter plate 
reader (SPECTROstar Nano, BMG Labtech, Ortenberg, 
Germany). Fresh medium (200  µl LCM) was used for 
background calibration. For calculation of the growth 
ability in the presence of antifungal proteins or drugs, 
the absorbance of the untreated control cultures (100 µl 
LCM mixed with 100 µl of 105 cells or conidia or sporan-
giospores ml−1 suspension prepared in LCM) were set 
to be 100 % growth. The minimal inhibitory concentra-
tion (MIC) was defined as the lowest antifungal protein 
or drug concentration at which growth was not detected 
after 24 (yeasts and R. miehei) or 48 h (Aspergillus spp.) 
of incubation on the basis of the OD620 values as com-
pared to the untreated control. All susceptibility tests 
were repeated three times with three replicates.
Investigation of the manifestation of antifungal 
mechanism
All investigations were performed on mid-log phase S. 
cerevisiae cells grown up in LCM at 30  °C under con-
tinuous shaking at 210  rpm. To reveal the short- and 
long-term antifungal effect of NFAP2, 105 cells ml−1 
were incubated in fresh LCM broth supplemented with 
the lethal (0.195  µg  ml−1) or sublethal (0.098  µg  ml−1) 
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concentration of NFAP2 for 10, 30, 60 min and 4, 6 and 
16 h at 30 °C. LCM without NFAP2 was used as control.
To compare the metabolic activity of the NFAP2-
treated and untreated cells, FUN1 viability staining 
(Thermo Fisher Scientific, Waltham, MA, USA) was used 
based on the manufacturer’s instructions.
To determine the proportion of apoptotic and necrotic 
cells in NFAP2-treated and untreated samples the 
Annexin V-FITC (fluorescein isothiocyanate) Apoptosis 
detection kit (Sigma-Aldrich, St Louis, MO, USA) was 
used following the manufacturer’s instructions.
Plasma membrane disrupting activity of NFAP2 was 
investigated by applying the membrane impermeant, 
red-fluorescent nuclear and chromosome stain propid-
ium iodide (PI). Cells were washed with LCM, and then 
stained with 5 µg ml−1 PI for 10 min at room tempera-
ture in the dark, and then washed again with LCM. Cells 
treated with 70 % (v/v) ethanol for 30 min at 4  °C were 
used as positive staining control.
Total and Annexin- or PI-positive cell numbers were 
determined in a Bürker chamber. All experiments were 
performed in three independent replicates.
Microscopy
Cells were visualized by light and fluorescence micros-
copy (Carl Zeiss Axiolab LR 66238C; Zeiss, Oberkochen, 
Germany) and photographed with a microscope camera 
(Zeiss AxioCam ERc 5 s; Zeiss, Oberkochen, Germany).
Heat stability investigation
Heat stability of NFAP2 was investigated on S. cerevi-
siae in microtiter plate bioassay. NFAP2 diluted in LCM 
(0.78–0.049  µg  ml−1 in twofold dilution) was continu-
ously heated from 25 to 95  °C, and then was incubated 
at the final temperature for 5  min. After cooling down 
to room temperature for 30  min, 100  µl treated protein 
solution was mixed with 100  µl 105 mid-log phase cells 
ml−1 grown up at 30  °C under continuous shaking at 
210 rpm and diluted in LCM, then filled in the well of a 
flat-bottom microtiter plate. The microtiter plate was 
incubated at 30 °C for 24 h without shaking. The growth 
ability of S. cerevisiae was determined as described pre-
viously in the antifungal susceptibility tests. Untreated 
NFAP2 and S. cerevisiae culture (100 µl LCM mixed with 
100 µl 105 ml−1 mid-log phase cells) were used as activity 
and growth controls, respectively. The test was repeated 
three times with two replicates.
Electronic circular dichroism spectroscopy and structural 
investigation
Secondary structure and thermal stability of NFAP2 
was examined by electronic circular dichroism (ECD) 
spectroscopy. Measurements were performed in the 
195–260  nm wavelength range using a Jasco-J815 spec-
tropolarimeter (JASCO, Tokyo, Japan). The protein 
sample was presented in pure water in approximately 
0.1 mg ml−1 concentration in a 0.1 cm path length quartz 
cuvette. First, the ECD spectrum of the sample was 
recorded at 25  °C with a scan speed of 100 nm s−1. The 
temperature was then gradually increased up to 95 °C at a 
rate of 1 °C min−1 using a Peltier thermo electronic con-
troller (TE Technology, Traverse City, MI, USA), while 
ellipticity data was recorded as a function of temperature 
at three wavelengths, appointed by the extrema of the 
spectrum measured at 25 °C. The system was allowed to 
equilibrate for 1 min, before measurements were taken at 
each temperature point.
The resultant melting curves were fitted with a sym-
metrical sigmoidal function of which inflexion point cor-
responds to the melting temperature (Tm) of the protein 
structure.
At the final temperature, 95  °C, ECD spectrum in the 
195-260 nm range was recorded again and then the sam-
ple was left to cool to 25  °C. Further spectrum acquisi-
tions were done at 25  °C 1 min after cooling, then after 
72  h and then 4  weeks later. The reported spectra are 
accumulations of ten scans, from which the similarly 
recorded, corresponding solvent spectrum was sub-
tracted. Ellipticity data are given in mdeg units.
For determination of possible disulfide bond pat-
tern of NFAP2, reversed-phase high performance liq-
uid chromatography (RP-HPLC) runs were carried out 
on a Phenomenex Jupiter C18 column (250 × 4.6 mm; 
10  μm particle size; 300  Å pore size; Phenomenex, 
Torrance, CA, USA) using an Agilent 1100 Series liq-
uid chromatograph (Agilent Technologies, Little Falls, 
DE, USA). Linear gradient elution was carried out 
with 0.1 % (v/v) TFA in water (eluent A) and 80 % (v/v) 
acetonitrile and 0.1  % (v/v) TFA is water (eluent B) 
from 5 to 40 % (v/v) (B) over 35 min at a flow rate of 
1.0 ml min−1.
Statistical analysis
Statistical analysis was performed using Microsoft Excel 
2010 software (Microsoft, Edmond, WA, USA). Two 
sample t test was used to reveal significance between 
treated and untreated samples.
Results
Isolation and identification of NFAP2
N. fischeri NRRL 181 secreted an anti-yeast protein into 
the supernatant when it was cultivated in MM. After 
purification, protein gel electrophoresis revealed the 
presence of a ~5.6  kDa protein in the pooled fractions 
which showed anti-yeast activity (Fig. 1). Presence of any 
other proteins (even NFAP) was not detected with silver 
Page 5 of 13Tóth et al. AMB Expr  (2016) 6:75 
staining (Additional file 1: Fig. S1) and MS analysis in the 
purified sample. Mass spectrometric molar mass meas-
urement of this protein resulted 5555.5513  Da (Fig.  2a) 
which showed good correlation with its appearance 
on the protein gel (Fig.  1). The average yield of purified 
NFAP2 was 368 ± 19 µg l−1 (n = 5).
Processed data from MS analysis of enzymatic digested 
NFAP2 was subjected to database searching using Mas-
cot search engine. This revealed a partial sequence of the 
examined protein. An IATSPYYACNCPNNCK peptide 
fragment of a hypothetical protein from N. fischeri NRRL 
181 was identified (Fig. 2b).
BLAST search for this identified fragment on the 
submitted N. fischeri NRRL 181 genome in the Uni-
Prot and NCBI databases resulted in an uncharacter-
ized, hypothetical protein (accession numbers: A1DBL3 
and XP_001262150.1, respectively) (Fig.  2c). The meas-
ured molecular mass of the purified anti-yeast pro-
tein corresponded well to the calculated mass of the IA 
TSPYYACNCPNNCKHKKGSGCKYHSGPSDKSKVISG 
KCEWQGGQLNCIAT fragment of this hypothetical 
protein. The identified 5.6  kDa-protein was termed as 
Neosartorya fischeri antifungal protein 2 (NFAP2), and its 
encoding cDNA sequence was submitted in the EMBL-
EBI ENA nucleotide sequence database under LT160067 
accession number.
In silico investigations of NFAP2
Based on in silico investigations NFAP2 is expressed as 
an 86 amino acid length pre-pro protein and 21 amino 
acids length extracellular signal sequence, and additional 
13 amino acids are cleaved from the N-terminal end of 
the protein during the maturation process (Fig.  2c). 
The mature form of NFAP2 consists of 52 amino acids 
Fig. 1 Appearance of the NFAP2 in 18 % (w/v) tris–glycine sodium 
dodecyl sulfate–polyacrylamide gel (Novex™ 18 % Tris–Glycine Mini 
Protein Gels, 1.0 mm, 10-well; Thermo Fisher Scientific, Waltham, MA, 
USA) stained with Coomassie Brilliant Blue R-250. Lane 1: purified 
NFAP2 (1.5 μg), lane 2: Low-range Amersham Rainbow Marker (GE 
Healthcare Life Sciences, Little Chalfont, UK)
Fig. 2 ESI-MS (electrospray ionization mass spectrometry) spectrum of the purified NFAP2 (a), and MS/MS spectrum of its N-terminal IATSPYYAC-
NCPNNCK peptide fragment where the first ten amino acids were identified (b). In this peptide C11 and C15 formed an internal disulfide bridge 
due to the incomplete carbamidomethylation. Amino acid sequence of NFAP2 (c), where arrow indicates the cleavage site of the predicted signal 
sequence, the first amino acid of the mature protein is marked by an asterisk. Identified peptide by the MS analysis of enzyme digested NFAP2 is 
underlined. Connected cysteines indicates the predicted disulfide bridge formations
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(Fig. 2c) and has a calculated molecular mass of 5564.3 Da 
and pI of 9.02. NFAP2 is hydrophilic (GRAVY = −0.731) 
and positively charged (net charge at pH 7.0 = + 5.2) in 
the consequence of the R/K/D/E =  0/7/1/1 amino acid 
ratio. The six cysteines at position of 9, 11, 15, 23, 40 and 
49 form three disulfide bridges between C9 and C23, C11 
and C40, C15 and C49 showing abcabc pattern.
Phylogenetic relationships of NFAP2 to other antifungal 
proteins
Amino acid sequence of the mature NFAP2 shows 
11–21  % identity to the described, isolated and char-
acterized PAF-, and BP-cluster cysteine-rich antifun-
gal proteins from filamentous ascomycetes (Fig.  3a). 
BLAST searches yielded 35 protein sequences with sig-
nificant similarity to NAFP2 in published Ascomycota 
genomes (Additional file  1: Table S1; Fig. S2). The pre-
dicted mature forms of these putative proteins show 
35-98 % amino acid identity to NFAP2 (Additional file 1: 
Fig. S2). Until now, none of these NFAP2 homologs has 
been isolated and described, NFAP2 is the first one. Next, 
we were interested in the phylogenetic relationships 
of NFAP2 to PAF-, and BP-cluster proteins. Thus we 
inferred the phylogeny of antifungal proteins comprising 
the NFAP2, its detected homologs, and isolated PAF- and 
BP-cluster proteins. We found that the antifungal pro-
teins included in the analyses separated into three major 
groups, one including the BP-cluster proteins (Group 1—
blue in Fig. 3b), a second including PAF-cluster proteins 
(Group 2—yellow in Fig.  3b) and another that included 
NFAP2 and its detected homologs (Group 3—green 
in Fig.  3b). Statistical support for these three clades is 
moderate, which is not surprising given the short align-
able sequences of these proteins. However, the inferred 
grouping was consistent across several analyses and with 
previous phylogenetic results (Seibold et  al. 2011; Gal-
góczy et al. 2013a; Garrigues et al. 2016). It is noteworthy 
that Garrigues et  al. (2016) distinguished two groups in 
the clade containing PAF-related proteins (Group 2—yel-
low in Fig. 3b). These two groups are discernable on our 
phylogeny too, although they do not form monophyl-
etic sister clades. Taken together, observations made by 
Garrigues et al. (2016) and by us are consistent with the 
existence of four groups, although rigorous testing of the 
existence of class-level clades will require closer scru-
tiny in future studies. Nevertheless, our results clearly 
indicate that NFAP2 forms a new, phylogenetically dis-
tinct group among antifungal proteins found in Acremo-
nium, Alternaria, Aspergillus, Byssothecium, Claviceps, 
Coniochaeta, Daldinia, Eutypa, Fusarium, Hypoxylon, 
Karstenula, Massarina, Melanomma, Myriangium, Neo-
sartorya, Niesslia, Penicillium, Paraconiothyrium, Pseud-
ogymnoascus, Sordaria, and Thozetella species suggesting 
that NFAP2 homologs function in a phylogenetically 
diverse set of Ascomycota fungi.
Antifungal susceptibility tests
MICs of NFAP2, NFAP and conventional antifungal 
agents for the investigated fungal isolates are shown in 
Table 1.
The MICs of NFAP2 for yeasts were in the range of 
0.195–1.563  µg  ml−1, where S. cerevisiae proved to be 
the most (MIC: 0.195  µg  ml−1), and C. krusei the least 
(MIC: 1.563  µg  ml−1) susceptible. MIC values varied 
between 0.391 and 1.563  µg  ml−1 for clinically relevant 
Candida species, and these values did not change after 
prolonged incubation time (at 48 and 72 h). Yeasts were 
not susceptible to NFAP in its investigated concentration 
range. In contrast to these results, the applied concentra-
tions of NFAP could inhibit the growth of A. nidulans 
and A. niger (MIC: 200 and 50  µg  ml−1, respectively), 
and NFAP2 was ineffective against all filamentous fun-
gal isolates in the investigated concentration range. Total 
growth inhibition of R. mieheii was not observed in the 
presence of NFAP. Previously this strain proved to be 
slightly sensitive (Kovács et al. 2011) or resistant (Virágh 
et al. 2014) to this protein depending on the applied test 
medium.
To compare the efficacy of NFAP2 with the different 
types of conventional antifungal agents, the susceptibil-
ity of yeast isolates were also tested to AMB, CSP, FLC, 
ITC, and TRB. In the applied concentration range AMB 
(MIC: 4–8 µg ml−1) and CSP (MIC: 8–32 µg ml−1) were 
able to inhibit their growth, but resistances to FLC (MIC: 
8– >64 µg ml−1), ITC (MIC: 2– >64 µg ml−1), and TRB 
(MIC: 16– >64 µg ml−1) were observed, except of C. guil-
liermondii which proved to be sensitive to all antifungal 
drugs.
Characterization of the antifungal mechanism of NFAP2
The manifestation of antifungal mechanism of NFAP2 on 
yeast cells was investigated at its sublethal and lethal con-
centrations. Physiological changes in cells in the presence 
of an antifungal can be investigated at its sublethal con-
centrations which do not kill the fungus.
The two-colour fluorescent FUN1 stains the cyto-
plasm and metabolically inactive vacuoles green, while 
the metabolically active ones red. Based on the propor-
tion of the red and green vacuoles between the treated 
and untreated samples (data not shown), change in the 
metabolic activity of S. cerevisiae was not detected in the 
presence of sublethal NFAP2 concentration even after 
16 h-long NFAP2 treatment.
Annexin V-FITC Apoptosis Detection Kit dyes 
the apoptotic cells green, while the necrotic cells are 
counterstained red by the membrane impermeant, 
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Fig. 3 Alignment of isolated and characterized cysteine-rich antifungal proteins from filamentous ascomycetes (a). Based on the amino acid simi-
larity they are separated into three different groups (PAF-, BP-, and NFAP2-cluster proteins), and further four different subgroups are distinguishable 
in the PAF-cluster proteins. Maximum likelihood tree of isolated PAF- and BP-cluster proteins, and NFAP2 and its homologs detected through BLAST 
searches in published fungal genomes (b). ML bootstrap values >50 % are shown next to branches, all bootstrap values are available on Additional 
file 1: Fig. S3. The antifungal proteins included in the phylogenetic analyses separated into three major clades, Group 1 (BP-cluster proteins, blue), 
Group 2 (PAF-cluster proteins, yellow) and Group 3 (NFAP2 and its homologs, green). The presence of four different subgroups of PAF-cluster proteins 
is also supported by the phylogenetic tree. Abbreviations of isolated and characterized proteins: AcAFP, Aspergillus clavatus VR1 antifungal protein 
(Acc. No.: A1CSS4), AcAMP, Aspergillus clavatus ES1 antimicrobial peptide (Acc. No.: D3Y2M3), AFP, Aspergillus giganteus MDH 18894 antifungal 
protein (Acc. No.: P17737), AFPNN5353, Aspergillus giganteus A3274 antifungal protein (Acc. No.: not available, Binder et al. 2011); AFPB, Penicillium 
digitatum CECT 20796 antifungal protein (Acc. No.: K9FGI7); ANAFP, Aspergillus niger KCTC 2025 antifungal protein (Acc. No.: A2QM98); BP, Penicillium 
brevicompactum Dierckx ‘bubble protein’ (Acc. No.: G5DC88); FPAP, Fusarium polyphialidicum SZMC 11042 antifungal protein (Acc. No.: E1UGX4); NAF, 
Penicillium nalgiovense BFE 66, 67, 474 antifungal protein (Acc. No.: not available, Geisen 2000); NFAP, Neosartorya fischeri NRRL 181 antifungal protein 
(Acc. No.: D4YWE1); NFAP2, Neosartorya fischeri NRRL 181 antifungal protein 2 (Acc. No.: A1DBL3); PAF, Penicillium chrysogenum Q176 antifungal 
protein (Acc. No.: B6HWK0); Pc-Arctin, Penicillium chrysogenum A096 ‘bubble protein’ (Acc. No.: CAP96194); PgAFP, Penicillium chrysogenum RP42C 
antifungal protein (Acc. No.: D0EXD3). The Acc. No. or Protein ID of the putative protein is indicated in the panel b at NFAP2 homologs. For further 
information (species name, sequence, etc.) see Additional file 1: Table S1
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red-fluorescent nuclear and chromosome stain PI, and 
living cells do not show any fluorescence. There was no 
significant difference between the proportion of green 
cells in the NFAP2-treated and untreated samples (ca. 
1  % of the total cell number) even after 16  h (data not 
shown). In short exposure time (10, 30 and 60  min) at 
sublethal NFAP2 concentration, same percent of the cells 
was counterstained with PI in the treated and untreated 
samples (ca. 1 % of the total cell number), but after 16 h 
of incubation three times more red cells were counted in 
the treated sample than in the untreated control reach-
ing a statistically significant difference (p  =  0.00004). 
Based on this last observation we suggested that NFAP2 
cannot induce apoptosis in the yeast cells, but can dis-
rupt the plasma membrane. It was verified with a simple 
PI-staining.
During 6  h exposure to sublethal NFAP2 concentra-
tion, same percent of the total cell number showed red 
fluorescence as in the untreated control. In contrast to 
this, at 16  h the 6  % of the total cell number were PI-
positive in the untreated control compared to the sam-
ple treated with sublethal concentration of NFAP2 where 
it was 18  % (Fig.  4a, c). At this time point the total cell 
number reduced to ca. 60 percent of the untreated con-
trol in the presence of NFAP2 (data not shown). When 
the cells were exposed to lethal concentration of NFAP2, 
significant differences were observed in the number of 
PI-positive cells between the NFAP2-treated sample and 
the untreated control already after 10 min of incubation 
(Fig. 4b, c). After 16 h, viable cells were not observed in 
the NFAP2-treated sample (Fig. 4c).
Taking these observations into consideration the anti-
fungal mechanism of NFAP2 results in plasma mem-
brane disruption and the timing of this activity depends 
on the applied concentration.
Thermal stability of NFAP2 and preliminary structural 
investigations
After continuous heating and 5 min exposure at 95  °C, 
NFAP2 maintained its antifungal activity against S. cer-
evisiae with a one dilution step shift in the MIC from 
0.195 to 0.391 µg ml−1 presumably due to its folded and 
disulfide bond-stabilized compact tertiary structure. 
To prove this hypothesis we performed thermal unfold-
ing experiments monitored by far-UV electronic circu-
lar dichroism (ECD) spectroscopic measurements and a 
conformational RP-HPLC analysis.
ECD spectrum of NFAP2 at 25 °C shows features simi-
lar to spectra of the homologous PAF protein (Fizil et al. 
2015) and other disulfide bridged, β-structured proteins 
(Lees et al. 2006) (Fig. 5a) The spectrum has two maxima 
at 200  nm and 228  nm and a low intensity minimum 
centering at 212  nm. The maximum at 200  nm reflects 
β-conformation and contributions from the spectral 
transitions of disulfide bridges. The maximum at 228 nm 
is mainly attributed to the disulfide bridges while the 
low intensity minimum at 212  nm is, again, indicates 
β-conformation. The spectrum measured at 95 °C reflects 
Table 1 In vitro minimal inhibitory concentration (MIC) values of  NFAP2, NFAP and  conventional antifungal agents 
for the investigated fungal isolates
MIC was determined after 24 h (yeasts and R. miehei CBS 360.92) and 48 h (Aspergillus spp.) of incubation. Abbreviations: AMB amphotericin B, CSP caspofungin, FLC 
fluconazole, ITC itraconazole, NFAP Neosartorya fischeri antifungal protein, NFAP2 Neosartorya fischeri antifungal protein 2, TRB terbinafine
Fungus MIC (µg ml−1)
NFAP2 NFAP AMB ITC FLC TRB CSP
Yeasts
 Candida albicans ATCC 10231 0.781 >200 8 >64 >64 64 16
 Candida glabrata CBS 138 0.391 >200 8 >64 >64 64 16
 Candida guilliermondii CBS 566 0.391 >200 4 2 8 16 16
 Candida krusei CBS 573 1.563 >200 8 2 >64 64 16
 Candida lusitaniae CBS 6936 0.781 >200 8 16 >64 16 16
 Candida parapsilosis CBS 604 0.391 >200 8 2 >64 16 32
 Candida tropicalis CBS 94 0.391 >200 8 >64 >64 >64 8
 Saccharomyces cerevisiae SZMC 0644 0.195 >200 4 2 64 >64 16
 Schizosaccharomyces pombe SZMC 0142 0.391 >200 4 8 64 >64 16
Filamentous fungi
 Aspergillus nidulans FGSC A4 >25 200 >64 4 >64 8 >64
 Aspergillus niger SZMC 601 >25 50 8 8 >64 16 >64
 Rhizomucor mieheii CBS 360.92 >25 >200 2 1 16 8 8
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the total loss of ordered secondary structure. The disap-
pearance of the intense positive band at 228 nm indicates 
either conformational change (Hider et  al. 1988) or the 
UV light-induced disruption of disulfide bridges at high 
temperature. It has been reported that UV excitation of 
aromatic residues may result in electron or H ejection 
Fig. 4 Propidium iodide (PI) staining of S. cerevisiae cells after sublethal (0.089 µg ml−1) NFAP2 treatment for 16 h at 30 °C (a) and lethal 
(0.195 µg ml−1) NFAP2 treatment for 10 min at 30 °C (b). Intracellular red fluorescence indicates membrane disruption. c Untreated control, NFAP2: 
NFAP2-treated cells. Scale bars represent 20 μm. Proportion of the PI-positive S. cerevisiae cells in the sublethal and lethal NFAP2-treated and 
untreated samples after different incubation times at 30 °C (c). Significant differences (p-values) were determined based on the comparison with 
the untreated control. ***p < 0.0001, **p < 0.005, *p < 0.05, ns no significant difference
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which can reduce adjacent disulfides (Neves-Petersen 
et al. 2002). After the cooling of NFAP2 solution back to 
25 °C moderate structural reorganization takes place, but 
this reorganization is incomplete even 4 weeks after the 
annealing. Thermal unfolding curves (Fig.  5b) indicate 
remarkable thermal stability of this protein. The native 
fold remains intact up to 70  °C, although thermal dena-
turation is irreversible.
MS data already indicated that the cysteine residues 
were oxidized and intra-molecular disulfide bonds 
could be formed between them. To prove it and reveal 
the possible disulfide bond pattern of NFAP2 an RP-
HPLC method was applied. It is known that RP-HPLC 
has the ability to correlate the retention behavior of 
peptides and proteins with their conformation. Based 
on this finding as well as on our experience on folding 
of P. chrysogenum antifungal protein PAF (Váradi et al. 
2013), disulfide bond formation of NFAP2 was followed 
by reversed-phase liquid chromatography. Figure  5c 
shows RP-HPLC elution profiles of folded NFAP2 and 
PAF measured under the same conditions. NFAP2 and 
PAF share structural similarities concerning their cati-
onic character and the number of amino acids they 
are composed of. Both proteins are stabilized by three 
disulfide bridges. The common abcabc disulfide bond 
pattern has already been proven for PAF, and naturally 
folded PAF was shown to have much smaller reten-
tion time on RP-HPLC than any other variant possess-
ing unnatural disulfide bond pattern (Batta et  al. 2009; 
Váradi et  al. 2013). Considering that NFAP2 elutes 
from the reversed-phase column as early as naturally 
folded PAF, the same interlocking disulfide bond pattern 
(abcabc) seems to be the most probable for NFAP2 as 
we predicted in silico (Fig. 2c).
Fig. 5 ECD spectra of NFAP2 recorded at 25 °C (black), 95 °C (red), and again at 25 °C immediately (blue), 72 h (green) and 4 weeks (orange) after heat 
treatment (a). Thermal unfolding curves of NFAP measured at 200 nm (black, R2 = 0.9899, Tm = 76.60 °C), 212 nm (red, R2 = 0.9770, Tm = 72.49 °C) 
and 228 nm (blue, R2 = 0.9910, Tm = 74.00 °C) (b). RP-HPLC chromatogram of NFAP2 and its comparison with folded and unfolded PAF (c)
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Discussion
In this work we proved that the N. fischeri NRRL 181 is 
able to secrete an anti-yeast protein (NFAP2) in addition 
to the previously well-characterized, anti-mold NFAP 
(Kovács et  al. 2011; Galgóczy et  al. 2013b; Virágh et  al. 
2014, 2015). When N. fischeri NRLL 181 was cultivated 
in a minimal medium, NFAP2 could be purified from the 
supernatant with the same single-step method that we 
applied at NFAP (Virágh et  al. 2014), and the presence 
of NFAP was not observable. Similarly, when N. fischeri 
NRLL 181 was cultivated in a complete medium (Kovács 
et  al. 2011) only the NFAP was present in the superna-
tant. These results indicate that the antifungal protein 
profile of N. fischeri NRRL 181 highly depends on the cul-
tivation medium.
NFAP2 and its detected putative homologs represent 
a phylogenetically distinct, new group of cysteine-rich 
antifungal proteins from filamentous ascomycetes beside 
the BP- and PAF-cluster proteins (Fig.  3b) and a puta-
tive fourth group (see Garrigues et al. 2016), and they are 
widespread among filamentous ascomycetes (Additional 
file 1: Table S1; Fig. S2). The antifungal spectrum of PAF- 
and BP-cluster proteins is differing (Marx 2004; Galgóczy 
et  al. 2010; Seibold et  al. 2011; Chen et  al. 2013). They 
have a potent antifungal activity on molds, and show no 
(Marx 2004; Galgóczy et al. 2010) or weak activity against 
yeasts (Lee et al. 1999; Seibold et al. 2011; Galgóczy et al. 
2013a). In the genome of N. fischeri NRRL 181, a puta-
tive BP-cluster protein encoding gene was identified, the 
Neosartorya fischeri ‘bubble protein’ (NFBP, Acc. No.: 
A1DKX1) (Fig. 3a) (Seibold et al. 2011). Based on our in 
silico a prediction by the SignalP1 4.1 server (Petersen 
et  al. 2011), NFBP is also a secreted protein (data not 
shown). Considering this arsenal of various extracellular 
antifungal proteins with different antifungal spectrum, 
presence of a complex antifungal mechanism in N. fis-
cheri is hypothesized to fight against other fungi. The role 
and other biological function in addition antifungal toxic-
ity is supposed at PAF. It can modulate the asexual devel-
opment in P. chrysogenum (Hegedüs et al. 2011). Similar 
or other physiological role of NFAP2 is also possible on 
the native producer, but its demonstration is waiting for 
further investigations.
NFAP2 was secreted in small yield by N. fischeri NRRL 
181 into the culture medium comparing to NFAP where 
three-fold higher yield has been described (Kovács et al. 
2011; Virágh et  al. 2014). Although, considering that 
NFAP2 was able to inhibit the growth of different yeasts 
at its relative low concentrations, this yield is quite high. 
Different clinically relevant Candida species proved to 
be susceptible to NFAP2, which exerted fungicide activ-
ity on them (data not shown). In susceptibility tests clini-
cal reference strain of C. albicans and other emerged 
non-albicans Candia (NAC) which can cause serious 
cutaneous, mucosal and/or systemic infections were 
involved. At these species moderate or strong primary 
and secondary resistance to the conventional antifungal 
drugs is described (Papon et al. 2013). In our susceptibil-
ity tests some Candida isolates proved to be resistant to 
one or more conventional antifungal agents. If they were 
sensitive to them, the antifungal drugs showed higher 
MIC than NFAP2. The observed extremely low MICs and 
the fact that none of the investigated yeasts were resistant 
to NFAP2 render commercial utility as potential antifun-
gal for this protein.
In comparison, the anti-mold NFAP caused reduced 
metabolic activity and apoptosis induction in the sensi-
tive Aspergillus nidulans within a short exposure time 
(Virágh et al. 2015), while NFAP2 could not that suggests 
a different mode of action. Based on our observations it 
could be supposed that the main antifungal mechanism 
of NFAP2 on yeast cell is the disruption of the plasma 
membrane, however further experiments are required to 
prove this and to reveal the exact mode of action. Mem-
brane disruption activity of several cationic antimicro-
bial peptides from plants and human on C. albicans and 
NAC has been described (Nawrot et al. 2013; Swidergall 
and Ernst 2014). It is described that the membrane dis-
ruption ability of antimicrobial proteins is in tight con-
nection with the high abundance of arginine and lysine 
residues which render high positive charge to them (Lee 
and Lee 2015; Tam et al. 2015). Hence the same activity 
of NFAP 2 is corroborated by its cationic character (net 
charge is +5.2 at pH 7.0) due to the presence of seven 
lysine residues.
Similarly to NFAP (Kovács et  al. 2011), NFAP2 also 
proved to be heat-stable owing to its folded and disulfide 
bridge-stabilized tertiary structure. This structure is 
common within the group of ascomycetous cysteine-rich 
antifungal proteins and experimentally proved at AFP 
(Campos-Olivas et  al. 1995; Lacadena et  al. 1995); PAF 
(Batta et al. 2009); and BP (Olsen et al. 2004).
Results from this study render NFAP2 of antifungal 
highly interesting compounds for development of a new 
antifungal strategy against yeasts after further studies 
focusing on its bulk production, antifungal mechanism, 
toxicity and in vivo activity.
Additional file
Additional file 1. Supplementary materials. Fig. S1 Purity of the NFAP2 
after the ion-exchange chromatography, checked with 18 % (w/v) 
tris–glycine sodium dodecyl sulfate–polyacrylamide gel (Novex™ 18 % 
Tris–Glycine Mini Protein Gels, 1.0 mm, 10-well; Thermo Fisher Scientific, 
Waltham, MA, USA) electrophoresis. Table S1 Putative NFAP2 homologs 
from annotated filamentous Acomycota genomes. Fig. S2 Alignment of 
the putative NFAP2 homolog proteins from filamentous ascomycetes. Fig. 
S3 Bootstrap values of the maximum likelihood tree presented in Fig. 3b.
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